Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 ...
Current news releases distributed by PR Newswire APAC including multimedia press releases, investor relations and disclosure, and company news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback